Company Overview
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Why Investors Should Care
Revenue has grown at a 122.6% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $16.12M (+15.6% YoY); net profit $-73.60M.
- Trailing 12 Months Year-on-year growth — revenue -23.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 122.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 122.64% |
| 1 Year: | -23.40% |
Stock Price Performance
| 1 Year: | -10.14% |
| 6 Months: | +7.73% |
| 3 Months: | +8.94% |
| 1 Month: | -10.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)39.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 122.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SEER Seer, Inc. PHARMA | 1.95 | -1.60 | $107.98M | 0.00% | -27.82% | -26.45% | 122.64% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 177.00K | 71.00K | 72.00K | 62.00K | 1.33M | 2.15M | 3.31M | 3.62M | 3.96M | 4.05M | 4.01M | 4.16M | 3.07M | 3.07M | 4.03M | 4.14M | 3.93M | 3.97M | 4.07M | 2.71M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.14M | 1.94M | 2.01M | 2.02M | 1.81M |
| Gross Profit | - | 71.00K | 72.00K | 62.00K | 748.00K | 1.17M | 1.24M | 1.61M | 1.95M | 2.07M | 2.28M | 2.16M | 1.36M | 1.73M | 1.94M | 2.00M | 1.99M | 1.96M | 2.06M | 895.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.73M | 22.52M | 21.30M | 19.44M | 18.15M |
| Operating Income | -5.83M | -6.37M | -8.42M | -16.50M | -16.67M | -18.43M | -23.79M | -23.43M | -25.07M | -27.45M | -27.94M | -25.84M | -25.19M | -27.10M | -24.32M | -20.73M | -20.53M | -19.35M | -17.39M | -17.26M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.13M | -18.99M | -17.89M | -15.88M | -15.73M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.85M | -19.38M | -18.21M | -15.97M | -16.83M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 101.00K | 48.00K | 24.00K | 28.00K | 10.00K |
| Net Income | -5.49M | -6.12M | -8.23M | -16.43M | -16.62M | -18.39M | -23.65M | -22.82M | -23.98M | -23.96M | -23.43M | -21.09M | -20.68M | -22.85M | -21.33M | -19.95M | -19.42M | -18.23M | -15.99M | -16.84M |
| Diluted EPS | -0.61 | -0.63 | -0.80 | -0.27 | -0.27 | -0.30 | -0.38 | -0.37 | -0.38 | -0.38 | -0.37 | -0.33 | -0.32 | -0.35 | -0.35 | -0.34 | -0.33 | -0.32 | -0.29 | -0.30 |
| R&D Expense | 4.22M | 4.54M | 4.76M | 6.23M | 6.93M | 7.75M | 10.73M | 10.87M | 11.56M | 14.47M | 14.15M | 13.23M | 12.27M | 12.73M | 12.97M | 11.35M | 11.98M | 10.80M | - | 8.81M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 656.00K | - | 14.69M | 15.18M | 13.95M | 16.12M |
| Cost of Revenue | - | - | 8.40M | 8.15M | 7.12M | 8.11M |
| Gross Profit | 656.00K | - | 6.29M | 7.03M | 6.83M | 8.01M |
| Operating Expenses | - | - | 103.52M | 110.49M | 106.93M | 86.00M |
| Operating Income | -33.65M | - | -97.23M | -103.46M | -100.10M | -77.99M |
| EBITDA | - | - | -93.29M | -97.89M | -93.92M | -71.89M |
| Interest Expense | - | 22.00K | 0 | - | - | - |
| Pretax Income | - | - | -92.97M | -86.28M | -86.50M | -73.40M |
| Tax Provision | - | - | - | 0 | 98.00K | 201.00K |
| Net Income | -32.77M | - | -92.97M | -86.28M | -86.60M | -73.60M |
| Diluted EPS | -2.48 | - | -1.49 | -1.35 | -1.39 | -1.28 |
| R&D Expense | 18.94M | 29.12M | 45.80M | 53.02M | 50.59M | 43.87M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 442.32M | - | 487.93M | 436.27M | 366.60M | 296.08M |
| Current Assets | - | - | - | 434.98M | 330.51M | 253.32M | 201.53M |
| Cash & Equivalents | - | 333.58M | - | 53.21M | 32.50M | 40.75M | 47.28M |
| Inventory | - | - | - | 4.63M | 4.49M | 7.44M | 7.79M |
| Receivables | - | - | - | 4.32M | 4.83M | 4.00M | 4.28M |
| Total Liabilities | - | 10.71M | - | 40.94M | 39.37M | 39.03M | 36.78M |
| Current Liabilities | - | 8.09M | - | 12.58M | 13.22M | 15.33M | 15.69M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 29.87M | 28.26M | 25.96M | 23.65M |
| Total Equity | 87.68M | 431.61M | - | 446.99M | 396.90M | 327.57M | 259.31M |
| Shares Outstanding | - | - | - | 63.41M | 64.30M | 59.13M | 56.22M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.83M | - | -60.78M | -59.06M | -46.11M | -44.45M |
| Investing Cash Flow | -34.56M | - | -122.72M | 37.90M | 65.86M | 61.55M |
| Financing Cash Flow | 371.49M | - | 3.89M | 452.00K | -11.49M | -10.57M |
| Capital Expenditure | -4.53M | - | -10.27M | -7.31M | -3.58M | -1.80M |
| Free Cash Flow | -25.36M | - | -71.05M | -66.37M | -49.69M | -46.24M |
| Net Change in Cash | - | - | -179.60M | -20.71M | 8.25M | 6.53M |
| Share Buybacks | 13.00K | 35.00K | 20.00K | 13.00K | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | - | 42.8% | 46.3% | 49.0% | 49.7% |
| Operating Margin % | -5,129.4% | - | -662.1% | -681.5% | -717.7% | -483.9% |
| Net Margin % | -4,996.2% | - | -633.1% | -568.3% | -620.9% | -456.6% |
| ROE % | -7.6% | - | -20.8% | -21.7% | -26.4% | -28.4% |
| ROCE % | -7.7% | - | -20.5% | -24.5% | -28.5% | -27.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Softbank Group Corporation | 9.27% | 5.14M | $9.55M |
| 2 | Siren, L.L.C. | 4.44% | 2.46M | $4.57M |
| 3 | Acadian Asset Management. LLC | 3.53% | 1.95M | $3.63M |
| 4 | Vanguard Capital Management LLC | 3.31% | 1.83M | $3.41M |
| 5 | Blackrock Inc. | 2.58% | 1.43M | $2.66M |
| 6 | Renaissance Technologies, LLC | 1.78% | 985.50K | $1.83M |
| 7 | Nano Cap New Millennium Growth Fund L P | 1.49% | 825.00K | $1.53M |
| 8 | Citadel Advisors Llc | 0.94% | 519.31K | $965.92K |
| 9 | Two Sigma Investments, LP | 0.89% | 492.30K | $915.67K |
| 10 | Geode Capital Management, LLC | 0.83% | 460.43K | $856.40K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SEER
Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of Directors
HOUSTON, September 04, 2026--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to director Meeta Gulyani.…
Seer (SEER) Q2 2026 Earnings Call Transcript
Revenue grew to $3.1 million despite academic funding headwinds.
Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
HOUSTON, August 13, 2026--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the "Company"), today issued the following open letter to the Company’s Board of …
Seer Inc (SEER) (Q2 2026) Earnings Call Highlights: Navigating Funding Headwinds While ...
Seer Inc (SEER) reaffirms full-year guidance despite a year-over-year revenue dip, bolstered by strong cash reserves, groundbreaking independent validations, and promising AI cancer screening data.
Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended June…
Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genui…
SEER — Frequently Asked Questions
What is the current share price of Seer, Inc. (SEER)?
As of 2026-09-19 21:16 PDT, Seer, Inc. (SEER) trades at $1.95 on NasdaqGS. Its 52-week range is $1.62 to $2.37.
What is the market capitalisation of SEER?
Seer, Inc. (SEER) has a market capitalisation of $107.98M on NasdaqGS.
What is the P/E ratio of SEER?
SEER trades at a trailing price-to-earnings (P/E) ratio of -1.60. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.46.
What is the return on equity (ROE) of SEER?
SEER has a return on equity (ROE) of -26.45%. Its return on capital employed (ROCE) is -27.82%.
Is SEER a good stock to buy?
This page provides a data-driven analysis of Seer, Inc. (SEER), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.